{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:37:08Z","timestamp":1794328628488,"version":"4.9.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>The dual-target inhibitor strategy is an evolving approach that holds great potential for treating complex diseases by addressing their multifactorial nature. It can enhance therapeutic outcomes, reduce side effects and avoid the emergence of drug resistance, particularly in conditions like cancer, inflammation and neurological disorders, where multiple pathways contribute to disease progression. Identifying suitable targets for a dual inhibitor approach requires a deep understanding of disease biology, knowledge of critical pathways, and selection of complementary or synergistic targets. Human carbonic anhydrases (hCAs) have been recognized as suitable drug targets for this therapeutic approach. These enzymes play a key role in maintaining pH balance, ion transport, and fluid regulation across various tissues and organs and their dysregulation has been associated to a variety of human pathologies. Consequently, the inhibition of hCAs combined to the possibility to modulate the activity of a second molecular target represents a promising way for developing more effective drugs. In this mini-review, we aim to present an overview of the most significant structural results related to the development of novel therapeutics employing hCA inhibitors as dual-targeting compounds for the treatment of complex diseases.<\/jats:p>","DOI":"10.3389\/fmolb.2025.1511281","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:12:07Z","timestamp":1738559527000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Dual targeting carbonic anhydrase inhibitors as promising therapeutic approach: a structural overview"],"prefix":"10.3389","volume":"12","author":[{"given":"Katia","family":"D\u2019Ambrosio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Di Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Langella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1021\/cr200176r","article-title":"Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?","volume":"112","author":"Alterio","year":"2012","journal-title":"Chem. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/METABO10100412","article-title":"Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment","volume":"10","author":"Angeli","year":"2020","journal-title":"Metabolites"},{"key":"B3","doi-asserted-by":"publisher","first-page":"10010","DOI":"10.1021\/acs.jmedchem.3c00938","article-title":"First-in-Class dual targeting compounds for the management of seizures in glucose transporter type 1 deficiency Syndrome","volume":"66","author":"Angeli","year":"","journal-title":"J. Med. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1021\/acs.jmedchem.2c01911","article-title":"First-in-Class dual hybrid carbonic anhydrase inhibitors and transient receptor potential vanilloid 1 agonists revert oxaliplatin-induced neuropathy","volume":"66","author":"Angeli","year":"","journal-title":"J. Med. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1146\/annurev-pharmtox-010919-023238","article-title":"TRP channel cooperation for nociception: therapeutic opportunities","volume":"61","author":"Bamps","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.3390\/ijms21103421","article-title":"TRPV1: structure, endogenous agonists, and mechanisms","volume":"21","author":"Ben\u00edtez-Angeles","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7392","DOI":"10.1021\/ACS.JMEDCHEM.0C00636","article-title":"Azidothymidine \u201cclicked\u201d into 1,2,3-triazoles: first report on carbonic anhydrase-telomerase dual-hybrid inhibitors","volume":"63","author":"Berrino","year":"2020","journal-title":"J. Med. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2165\/00002512-199202030-00005","article-title":"Ocular \u03b2-blockers in glaucoma management: clinical pharmacological aspects","volume":"2","author":"Brooks","year":"1992","journal-title":"Drugs and Aging"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1021\/bi902178w","article-title":"Structures of human carbonic anhydrase II\/inhibitor complexes reveal a second binding site for steroidal and nonsteroidal inhibitors","volume":"49","author":"Cozier","year":"","journal-title":"Biochemistry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1021\/bi902178w","article-title":"Structures of human carbonic anhydrase II\/inhibitor complexes reveal a second binding site for steroidal and nonsteroidal inhibitors","volume":"49","author":"Cozier","year":"","journal-title":"Biochemistry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.2165\/00003495-200969110-00008","article-title":"Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis","volume":"69","author":"Croom","year":"2009","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2174\/0929867003374417","article-title":"Recent advances in inducible cyclooxygenase (COX-2) inhibition","volume":"7","author":"de Leval","year":"2000","journal-title":"Curr. Med. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1517\/13543776.12.7.969","article-title":"Advances in the field of COX-2 inhibition","volume":"12","author":"de Leval","year":"2002","journal-title":"Expert Opin. Ther. Pat."},{"key":"B14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/J.BMCL.2005.09.040","article-title":"Carbonic anhydrase inhibitors: valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II \u201cselective\u201d inhibitor celecoxib","volume":"16","author":"Di Fiore","year":"2006","journal-title":"Bioorg. and Med. Chem. Lett."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1080\/14756366.2020.1781846","article-title":"Human carbonic anhydrases and post-translational modifications: a hidden world possibly affecting protein properties and functions","volume":"35","author":"Di Fiore","year":"2020","journal-title":"J. enzyme inhibition Med. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1021\/jm0402059","article-title":"Adverse cardiovascular effects of the coxibs","volume":"48","author":"Dogn\u00e9","year":"2005","journal-title":"J. Med. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/0960-0760(95)00214-6","article-title":"Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application","volume":"55","author":"Elger","year":"1995","journal-title":"J. steroid Biochem. Mol. Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"112439","DOI":"10.1016\/J.EJMECH.2020.112439","article-title":"Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases","volume":"200","author":"Elzahhar","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.1038\/s41388-020-01405-w","article-title":"Targeting telomerase for cancer therapy","volume":"39","author":"Guterres","year":"2020","journal-title":"Oncogene"},{"key":"B20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrc2275","article-title":"Telomerase and cancer therapeutics","volume":"8","author":"Harley","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7406","DOI":"10.1021\/acs.jmedchem.4c00239","article-title":"Discovery and mechanistic studies of dual-target hits for carbonic anhydrase IX and VEGFR-2 as potential agents for solid tumors: X-ray, in vitro, in vivo, and in silico investigations of coumarin-based thiazoles","volume":"67","author":"Hefny","year":"2024","journal-title":"J. Med. Chem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40265-020-01429-2","article-title":"TRPV1-Targeted drugs in development for human pain conditions","volume":"81","author":"Iftinca","year":"2021","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/SJ.BJC.6601591","article-title":"Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents","volume":"90","author":"Ireson","year":"2004","journal-title":"Br. J. cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.BBRC.2016.07.114","article-title":"Structural insight into the inhibition of carbonic anhydrase by the COX-2-selective inhibitor polmacoxib (CG100649)","volume":"478","author":"Kim","year":"2016","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/epi4.12414","article-title":"Glut1 deficiency Syndrome (Glut1DS): state of the art in 2020 and recommendations of the international Glut1DS study group","volume":"5","author":"Klepper","year":"2020","journal-title":"Epilepsia Open"},{"key":"B26","doi-asserted-by":"publisher","first-page":"105920","DOI":"10.1016\/J.BIOORG.2022.105920","article-title":"A decade of tail-approach based design of selective as well as potent tumor associated carbonic anhydrase inhibitors","volume":"126","author":"Kumar","year":"2022","journal-title":"Bioorg. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00018-020-03697-3","article-title":"Intrinsically disordered features of carbonic anhydrase IX proteoglycan-like domain","volume":"78","author":"Langella","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1007\/s00018-018-2798-8","article-title":"Biochemical, biophysical and molecular dynamics studies on the proteoglycan-like domain of carbonic anhydrase IX","volume":"75","author":"Langella","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1021\/jm701319c","article-title":"Structure\u2013activity relationships of C-17 cyano-substituted estratrienes as anticancer agents","volume":"51","author":"Leese","year":"2008","journal-title":"J. Med. Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"7683","DOI":"10.1021\/jm060705x","article-title":"2-Substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity","volume":"49","author":"Leese","year":"","journal-title":"J. Med. Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"7683","DOI":"10.1021\/jm060705x","article-title":"2-Substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity","volume":"49","author":"Leese","year":"","journal-title":"J. Med. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/mus.10559","article-title":"Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy","volume":"29","author":"Lehky","year":"2004","journal-title":"Muscle Nerve"},{"key":"B33","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1042\/BJ20041037","article-title":"Crystal structure of human carbonic anhydrase II at 1.95 A resolution in complex with 667-coumate, a novel anti-cancer agent","volume":"385","author":"Lloyd","year":"","journal-title":"Biochem. J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"6858","DOI":"10.1021\/bi047692e","article-title":"First crystal structures of human carbonic anhydrase II in complex with dual Aromatase\u2212Steroid sulfatase inhibitors","volume":"44","author":"Lloyd","year":"","journal-title":"Biochemistry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrclinonc.2016.96","article-title":"Combine and conquer: challenges for targeted therapy combinations in early phase trials","volume":"14","author":"Lopez","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.2147\/DDDT.S257494","article-title":"Potential impact of the multi-target drug approach in the treatment of some complex diseases","volume":"14","author":"Makhoba","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1517\/13543776.2013.794788","article-title":"Antiglaucoma carbonic anhydrase inhibitors: a patent review","volume":"23","author":"Masini","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.2165\/11208240-000000000-00000","article-title":"Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis","volume":"71","author":"McCormack","year":"2011","journal-title":"Drugs"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1021\/acsmedchemlett.8b00352","article-title":"Tuning the dual inhibition of carbonic anhydrase and cyclooxygenase by dihydrothiazole benzensulfonamides","volume":"9","author":"Meleddu","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"B40","doi-asserted-by":"crossref","DOI":"10.4324\/9780203475300_chapter_8","volume-title":"Clinical applications of carbonic anhydrase inhibitors in ophthalmology","author":"Mincione","year":"2004"},{"key":"B41","first-page":"1209","article-title":"Advances in the discovery of novel agents for the treatment of glaucoma","volume-title":"Expert Opin. Drug Discov.","author":"Mincione","year":"2021"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1002\/MED.21713","article-title":"Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today?","volume":"40","author":"Mishra","year":"2020","journal-title":"Med. Res. Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1021\/acs.jmedchem.8b00625","article-title":"Discovery of \u03b2-adrenergic receptors blocker-carbonic anhydrase inhibitor hybrids for multitargeted antiglaucoma therapy","volume":"61","author":"Nocentini","year":"2018","journal-title":"J. Med. Chem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"11432","DOI":"10.1021\/acs.jmedchem.1c00756","article-title":"Mechanisms of the antiproliferative and antitumor activity of novel telomerase\u2013carbonic anhydrase dual-hybrid inhibitors","volume":"64","author":"Plyasova","year":"2021","journal-title":"J. Med. Chem."},{"key":"B45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1210\/ER.2004-0003","article-title":"Steroid sulfatase: molecular biology, regulation, and inhibition","volume":"26","author":"Reed","year":"2005","journal-title":"Endocr. Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"189120","DOI":"10.1016\/J.BBCAN.2024.189120","article-title":"Carbonic anhydrase IX: an atypical target for innovative therapies in cancer","volume":"1879","author":"Ronca","year":"2024","journal-title":"Biochimica biophysica acta. Rev. cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2165\/00003495-199958030-00016","article-title":"Rofecoxib","volume":"58","author":"Scott","year":"1999","journal-title":"Drugs"},{"key":"B48","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1517\/13543776.14.5.667","article-title":"Modulation of carbonic anhydrase activity and its applications in therapy","volume":"14","author":"Scozzafava","year":"2004","journal-title":"Expert Opin. Ther. Pat."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1001\/JAMA.282.20.1921","article-title":"Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial","volume":"282","author":"Simon","year":"1999","journal-title":"JAMA"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1158\/1078-0432.CCR-05-1996","article-title":"Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor","volume":"12","author":"Stanway","year":"2006","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/nar\/22.6.893","article-title":"The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena","volume":"22","author":"Strahl","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2174\/1389557043403792","article-title":"COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents","volume":"4","author":"Supuran","year":"2004","journal-title":"Mini Rev. Med. Chem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1042\/CS20210040","article-title":"Emerging role of carbonic anhydrase inhibitors","volume":"135","author":"Supuran","year":"2021","journal-title":"Clin. Sci. Lond. Engl. 1979"},{"key":"B54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4155\/FMC-2022-0249","article-title":"Latest advances in specific inhibition of tumor-associated carbonic anhydrases","volume":"15","author":"Supuran","year":"2023","journal-title":"Future Med. Chem."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1002\/MED.21497","article-title":"Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one","volume":"38","author":"Supuran","year":"2018","journal-title":"Med. Res. Rev."},{"key":"B56","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1517\/13543776.12.2.217","article-title":"Applications of carbonic anhydrase inhibitors and activators in therapy","volume":"12","author":"Supuran","year":"2002","journal-title":"Expert Opin. Ther. Pat."},{"key":"B57","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/MED.10025","article-title":"Carbonic anhydrase inhibitors","volume":"23","author":"Supuran","year":"2003","journal-title":"Med. Res. Rev."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1021\/acschembio.6b00304","article-title":"Inhibitor discovery for the human GLUT1 from homology modeling and virtual screening","volume":"11","author":"Ung","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e11794","DOI":"10.1097\/MD.0000000000011794","article-title":"The prognostic significance of hTERT overexpression in cancers: a systematic review and meta-analysis","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1007\/s11064-008-9750-5","article-title":"The functional regulation of TRPV1 and its role in pain sensitization","volume":"33","author":"Wang","year":"2008","journal-title":"Neurochem. Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"114039","DOI":"10.1016\/j.ejmech.2021.114039","article-title":"Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: a review","volume":"228","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"B62","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1021\/jm030912m","article-title":"Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition","volume":"47","author":"Weber","year":"2004","journal-title":"J. Med. Chem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/med.20141","article-title":"Therapeutic applications of glycosidic carbonic anhydrase inhibitors","volume":"29","author":"Winum","year":"2009","journal-title":"Med. Res. Rev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1158\/1535-7163.MCT-08-0195","article-title":"Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography","volume":"7","author":"Woo","year":"2008","journal-title":"Mol. cancer Ther."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1021\/jm901705h","article-title":"Highly potent first examples of dual Aromatase\u2212Steroid sulfatase inhibitors based on a biphenyl template","volume":"53","author":"Woo","year":"","journal-title":"J. Med. Chem."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1021\/jm901705h","article-title":"Highly potent first examples of dual Aromatase\u2212Steroid sulfatase inhibitors based on a biphenyl template","volume":"53","author":"Woo","year":"","journal-title":"J. Med. Chem."},{"key":"B67","doi-asserted-by":"publisher","first-page":"113300","DOI":"10.1016\/J.EJMECH.2021.113300","article-title":"Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR\/CAIX dual inhibitors","volume":"216","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1511281\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:12:11Z","timestamp":1738559531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1511281\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":67,"alternative-id":["10.3389\/fmolb.2025.1511281"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2025.1511281","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"article-number":"1511281"}}